Capital Research Global Investors Sells 1,151,654 Shares of Merck & Co., Inc. $MRK

Capital Research Global Investors trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK) by 33.3% during the third quarter, Holdings Channel.com reports. The institutional investor owned 2,310,615 shares of the company’s stock after selling 1,151,654 shares during the period. Capital Research Global Investors’ holdings in Merck & Co., Inc. were worth $193,930,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. DLD Asset Management LP bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at about $2,889,340,000. Norges Bank acquired a new position in Merck & Co., Inc. during the second quarter worth approximately $2,858,570,000. Franklin Resources Inc. raised its stake in Merck & Co., Inc. by 23.5% in the second quarter. Franklin Resources Inc. now owns 27,032,601 shares of the company’s stock valued at $2,139,901,000 after buying an additional 5,135,748 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in Merck & Co., Inc. by 35.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 19,456,096 shares of the company’s stock valued at $1,540,145,000 after buying an additional 5,094,088 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Merck & Co., Inc. by 9.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 53,865,466 shares of the company’s stock valued at $4,263,991,000 after buying an additional 4,636,183 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, CMO Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction on Monday, February 9th. The stock was sold at an average price of $118.41, for a total value of $1,184,100.00. Following the completion of the transaction, the chief marketing officer directly owned 70,615 shares of the company’s stock, valued at $8,361,522.15. The trade was a 12.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jennifer Zachary sold 121,573 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total value of $14,485,422.95. Following the sale, the executive vice president owned 68,916 shares of the company’s stock, valued at approximately $8,211,341.40. The trade was a 63.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 320,176 shares of company stock valued at $38,281,735 over the last ninety days. 0.13% of the stock is owned by corporate insiders.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive late‑stage clinical results across oncology and HIV programs — Phase 3 data for KEYTRUDA and WELIREG showed improved survival/expanded indications in kidney, ovarian and bladder cancer, and Merck highlighted progress on its DOR/ISL HIV program; these outcomes support revenue growth potential from high‑margin specialty drugs. Merck Trial Wins Shape Oncology And HIV Prospects For Investors
• Positive Sentiment: Recent earnings and guidance remain supportive — Merck posted an EPS beat and set FY2026 guidance, which underpins expectations for profitability and cash generation that fund R&D, buybacks, and dividends. (Earnings referenced from Merck’s Feb results.)
• Neutral Sentiment: Broader market reports note expanding markets for several of Merck’s products (neuroendocrine carcinoma, vaccines like Ervebo, M‑M‑R II, and fertility drug Elonva); these reports signal longer‑term TAM expansion but are not near‑term catalysts by themselves. Neuroendocrine Carcinoma Market Poised for Significant Growth Ervebo (Merck & Co) Market Research Report 2026 M-M-R II (Merck & Co) Market Research Report 2026 Elonva (Merck & Co) Market Research Report 2026
• Neutral Sentiment: Short‑term price momentum: recent coverage noted MRK moving higher within the S&P 500 and outperforming the market on some sessions — useful context for market positioning but not a fundamental change. Merck & Co. Moves Higher Within S&P 500 Index Amid Gains Merck (MRK) Rises Higher Than Market: Key Facts
• Negative Sentiment: Analyst caution on Winrevair — RBC flagged that Winrevair needs to show at least a 20‑meter improvement on the 6‑minute walk test to build confidence; failure to meet clinically meaningful thresholds could weigh on sentiment for that respiratory program. Merck’s Winrevair Must Show Walk Distance Improvement to Build Confidence, RBC Says

Merck & Co., Inc. Price Performance

NYSE:MRK opened at $116.21 on Thursday. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $125.14. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. The firm’s 50-day simple moving average is $114.86 and its 200 day simple moving average is $99.26. The firm has a market cap of $287.32 billion, a price-to-earnings ratio of 15.96, a P/E/G ratio of 2.27 and a beta of 0.27.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The firm had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. During the same quarter in the previous year, the firm posted $1.72 EPS. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be paid a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s payout ratio is 46.70%.

Analysts Set New Price Targets

MRK has been the topic of a number of recent analyst reports. Wolfe Research raised Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 target price on the stock in a report on Thursday, January 8th. TD Cowen increased their price objective on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a research report on Tuesday, January 20th. Citigroup lifted their target price on shares of Merck & Co., Inc. from $115.00 to $120.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Barclays began coverage on shares of Merck & Co., Inc. in a research note on Friday, February 20th. They issued an “overweight” rating and a $140.00 price target on the stock. Finally, Cantor Fitzgerald raised their price objective on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $125.88.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.